QuidelOrtho Corp (QDEL) filed a Form 4 reporting that its Chief Financial Officer, Joseph M. Busky, acquired company stock. On 11/24/2025, a trust for his benefit purchased 4,770 shares of QuidelOrtho common stock at a price of $26.0598 per share in an open-market transaction coded as a purchase. Following this trade, he beneficially owns 6,920 shares indirectly through the trust and 31,427 shares directly.
QuidelOrtho Corp (QDEL) director Mary Lake Polan reported an open-market purchase of company stock. On 11/21/2025, she bought 1,000 shares of common stock at a price of $22.43 per share in a transaction coded "P" for purchase. After this trade, she beneficially owns 12,640 shares directly and 17,353 shares indirectly through an LLC. The filing is a Form 4, which discloses changes in insider ownership.
QuidelOrtho Corporation reported insider equity activity for its Chief Legal Officer, Michelle A. Hodges. On November 18, 2025, 5,349 restricted stock units converted into the same number of common shares at $0 per share. On the same date, 2,717 common shares were disposed of at $21.28 per share to cover tax withholding obligations related to this vesting.
After these transactions, Hodges beneficially owned 32,035 shares of QuidelOrtho common stock directly and held 10,698 restricted stock units. Of these units, 5,349 shares vested on November 18, 2025 and the remaining 10,698 are scheduled to vest in equal installments on November 18, 2026 and November 18, 2027.
QuidelOrtho Corp (QDEL) reported an insider share purchase by its President and CEO, Brian J. Blaser. On 11/19/2025, he purchased 23,500 shares of common stock at a weighted average price of $21.3437 per share, with individual trade prices ranging from $20.91 to $21.72. After this transaction, he beneficially owned 29,533 shares indirectly through a trust and 11,451 shares directly. He also undertook to provide, upon request, detailed breakdowns of the number of shares purchased at each separate price.
QuidelOrtho Corporation furnished a stockholder letter via an 8-K. The letter from President and CEO Brian J. Blaser provides an update on results for the third quarter ended September 28, 2025 and is included as Exhibit 99.1.
The information, including Exhibit 99.1, is being furnished and is not deemed “filed” under the Exchange Act, which means it is not subject to Section 18 liability and is not incorporated by reference into other filings. The report was signed by CFO Joseph M. Busky. QuidelOrtho’s common stock trades on Nasdaq under the symbol QDEL.
QuidelOrtho Corporation reported a quarterly net loss of $733.0 million, largely due to a non-cash goodwill impairment of $700.7 million that eliminated all remaining goodwill. Total revenues were $699.9 million, down from $727.1 million a year ago, as lower Point of Care sales offset growth in Labs and Immunohematology.
Operating results reflected $39.6 million of restructuring, $47.7 million of intangible amortization, and $46.1 million in net interest expense. Year-to-date, the company recorded a net loss of $1,001.1 million and used $26.7 million in operating cash.
QuidelOrtho refinanced its capital structure on August 21, 2025, entering a new Credit Agreement with a $1.15B Term Loan A, $1.45B Term Loan B, and a $700.0M revolver; it repaid prior facilities and ended the quarter with $2.66B in total borrowings and $98.1 million in cash. Segment revenue was led by Labs $373.8M and Point of Care $164.6M. A final judgment related to a supplier dispute required payment of $10.8 million.
QuidelOrtho Corporation furnished an 8-K announcing its financial results for the third quarter ended September 28, 2025, and an earnings conference call. The company will host the call at 2:00 p.m. Pacific Time on November 5, 2025. A press release with the results is furnished as Exhibit 99.1. The information is furnished and not deemed filed under the Exchange Act.
QuidelOrtho (QDEL) reported insider equity activity by EVP of R&D & CTO Jonathan P. Siegrist. On 10/15/2025, 18,656 restricted stock units converted into common stock at $0 per unit. To cover taxes, 6,676 shares were withheld by the issuer at a price of $27.31.
Following these transactions, Siegrist directly holds 11,980 shares of common stock. He also holds 37,314 RSUs that will vest in equal installments on October 15, 2026 and October 15, 2027. Each RSU represents the right to receive one share of QuidelOrtho common stock.
QuidelOrtho (QDEL) reported an insider equity award event. Chief Legal Officer Michelle A. Hodges had 390 restricted stock units vest on October 15, 2025, converting into 390 common shares at $0. To cover tax withholding, 199 shares were withheld at $27.31. Following these transactions, she directly beneficially owned 29,403 common shares.
Ronald Lee Bowman, Chief Human Resources Officer of QuidelOrtho Corporation (QDEL), reported issuance and vesting activity on 09/15/2025. 2,565 restricted stock units (RSUs) vested and were released into common stock. To satisfy tax withholding obligations, the issuer withheld 918 shares (disposed at an effective price of $28.92 per share), leaving 1,647 shares of common stock directly owned by Bowman after the transaction. The filing also shows 5,132 RSUs remain outstanding and will vest in equal installments on 09/15/2026 and 09/15/2027. The Form 4 was signed by an attorney-in-fact on behalf of Bowman on 09/17/2025.